Many N-methyl-D-aspartate (NMDA) receptor antagonists have been used to treat neurodegenerative diseases induced by glutamate excitotoxicity in clinics. However, the universality of the glutamic acid neurotransmitter system makes the glutamic acid receptor blockers inefficient and unsafe. Thus, regulating the downstream signaling pathway in the excitotoxicity of glutamic acid may be a more effective and safer way to antagonize the glutamic acid receptor. In this study, we investigated the effect of deferoxamine (DFO), an iron chelator, on the NMDA-induced excitotoxicity. RGC-5 cells were cultured and identified in vitro, and the NMDA-induced injury was assessed. Then the MTT assay was used to estimate the cell survival and JC-1 staining was performed to detect changes in mitochondrial membrane potential. Immunofluorescent staining and western blot analysis were used to analyze the expressions of respiratory chain proteins. It was found that DFO increased the survival rate of RGC-5 cells and that this effect was positively correlated with the concentration of DFO and the treatment time. The mitochondrial membrane potential and the expression levels of succinate dehydrogenase subunit A and cytochrome c oxidase subunit IV were also increased after DFO treatment, while NMDA reduced their expression levels. These data demonstrate that DFO has significant neuroprotective activity against NMDA-induced excitotoxicity in RGC-5 cells.
Introduction
Glutamate is the major excitatory neurotransmitter in the central nervous system and in peripheral nervous system, which is involved in synaptic transmission, neuronal plasticity, outgrowth and survival [1] . Excessive stimulation of neurons by glutamate leads to neuronal injury or death, such as glaucomatous optic neuropathy [2] and auditory neuropathy [3] , a pathological process called glutamate excitotoxicity [4] . It has been suggested that high concentration of glutamic acid causes overstimulation of N-methyl-D-aspartate (NMDA) receptor in the neurons, leading to their death. Based on this, many NMDA receptor antagonists have been used to treat neurodegenerative diseases in clinics. However, the universality of the glutamic acid neurotransmitter system makes the glutamic acid receptor blockers inefficient and unsafe in clinical experiments. For example, memantine is used for Alzheimer's disease, and it is able to stabilize or slow down the decline in cognition, function, behavior, and global change, but the effect size is small in terms of efficacy outcomes [5] .
Thus, regulating the downstream signaling pathway in the excitotoxicity of glutamic acid may be a more effective and safer way to antagonize the glutamic acid receptor. It was found that elevated glutamic acid concentration caused cell death through an iron iondependent oxidative stress insult, and this mechanism shared a cell transduction pathway with the recently discovered non-apoptotic ferroptosis. In spinal cord anterior horn neurons cultured in vitro, glutamic acid-induced excitotoxicity may cause abnormalities in the iron ion metabolism system, including translocators, exportins, and storage proteins of iron ions [6] . This excitotoxicity also mediates mitochondrial injury through the iron ion metabolism system, and thus induces ferroptosis, apart from apoptosis, in neurons. Nowadays, retinal ganglion cell-5 (RGC-5) cells are often used to study neuronal injury or death [7, 8] .
In the present study, the effects of NMDA-induced injury on RGC-5 cells were assessed. The protective effect of adding deferoxamine (DFO) on the RGC-5 cells was investigated by estimating the changes in the mitochondrial membrane potential and the expression levels of respiratory chain proteins. The role of DFO in protecting nerves was demonstrated and its underlying mechanisms were explored.
Materials and Methods

Cell culture and treatment
The RGC-5 cell line was purchased from ATCC (Manassas, USA) and cultured in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin (Meiji Seika, Tokyo, Japan), and 10% FBS (Gibco-BRL, Grand Island, USA). Cells were grown in a humidified atmosphere with 5% CO 2 at 37°C. One passage was performed at a ratio of 1:4 every 3-4 days along with trypsin digestion.
In the study, RGC-5 cells were exposed to various concentrations (50-1600 μM) of NMDA (MCE, Jersey, USA) for 30 min, then cultured with the original culture medium for another 6 -24 h [9, 10] . NMDA receptor antagonist dizocilpine (MK801) (Sigma, San Louis, USA) was used to block NMDA excitotoxicity at 20 μM as reported by Hahn et al. [11] . Then various concentrations (5, 12.5, and 25 μM) of DFO (Calbiochem, La Jolla, USA) were used in the study. After treatment, cells were collected by centrifugation at 200 g for 5 min at room temperature, and used for the subsequent analysis.
Detection of cell survival by MTT assay
The collected cells were suspended in culture medium without FBS, and 150 μl of cell suspension was added into each well (1 × 10 5 cells/well) of a 96-well plate, with marginal wells filled with sterile PBS. The plate was incubated in a humidified atmosphere with 5% CO 2 at 37°C until a monolayer was formed on the flat bottom (70%-80% bottom area). MTT solution (20 μl, 5 mg/ml) was added into each well and incubated for another 4 h. The MTT formazan crystals were then dissolved in DMSO, and the absorption at 490 nm was measured using a Synergy HT multi-detection microplate reader (Bio-Rad, Hercules, USA). Each experiment was carried out independently in triplicate. Cell survival rate was calculated using the following formula:
Cell survival rate (%) = (A of the treatment group/A of the control group) × 100%.
Immunofluorescent staining
The collected cells were grown in six-well plates that were covered with cover glass in the bottom, and cultured in an incubator. Cell pieces were taken out after cell adherence, washed with PBS for 5 min, placed in stationary liquid (absolute ethyl alcohol:chloroform:glacial acetic acid = 6:3:1) for 20 min of fixation, followed by natural drying and washing with PBS buffer (0.01 M, pH 7.2) for 5 min for three times. Normal goat serum sealing fluid was added at room temperature for 20 min. 
Western blot analysis
The collected cells were lyzed on ice with RIPA buffer (Sigma-Aldrich) supplemented with a protease inhibitor cocktail (Sigma-Aldrich). After centrifugation, protein concentration in the supernatant was measured by a NanoDrop ND-2000 spectrophotometer (Thermo Fisher, Hudson, USA). Samples with equal amount of protein were resolved by SDS-PAGE, and then transferred onto nitrocellulose membranes (Bio-Rad).
The membranes were blocked with 3% non-fat milk in PBST (10 mM phosphate, 137 mM NaCl, 2.7 mM KCl, and 0.05% Tween-20, pH 7.4) for 60 min, and then incubated with the primary antibodies (1:400) for 2 h in PBST with 1% non-fat milk at room temperature. After extensive wash, membranes were incubated with HRP-conjugated secondary antibody (1:5000; Abcam) in PBST with 1% non-fat dry milk for 1 h at room temperature. Finally, membranes were detected using the clarity-enhanced chemiluminescence (ECL) reagent (Bio-Rad) and visualized using a ChemiDoc MP (Bio-Rad). The detection and quantification of band intensities were performed using the Image Lab 5.0 software (Bio-Rad).
Detection of mitochondrial membrane potential
The collected cells were resuspended in 500 μl 1× PBS. JC-1 dye (10 μg/ml; Merck, Kenilworth, USA) was added to the cells and incubated for 15 min at 37°C under 5% CO 2 . The excess dye was removed by washing with 1× PBS, and cells were analyzed by flow cytometry using the Becton Dickinson FACS Calibur and the CellQuest Software (Becton Dickinson, San Jose, USA) with the excitation wavelength at 488 nm.
Statistical analysis
The results are presented as the mean ± SD of a number of independent experiments. The P values were calculated using SPSS 19.0 software. Differences between multiple groups were evaluated using ANOVA. Correlations were deemed significant at P < 0.05 (twotailed).
Results
Cell culture and identification of RGC-5 cells
It was observed under a light microscope that RGC-5 cells were flat and irregular, and formed a monolayer of adherent growth. Immunofluorescent histochemical staining revealed positive Thy-1 expression in the membrane and cytoplasm of the cells, and blue DAPI staining revealed its presence in the nucleus. In addition, positive expressions of marker proteins Brn-3b and Thy-1 were detected by western blot analysis ( Fig. 1) . These results confirmed the successful cultivation of RGC-5 cells in our culture conditions.
NMDA induced apoptosis in RGC-5 cells
RGC-5 cells at the exponential growth phase were treated with NMDA at concentrations of 50-1600 μM and the cell survival rate was assessed at 6-48 h ( Fig. 2A) . Cell survival rate was found to be gradually inhibited by the treatment of NMDA at each condition (F = 103.75, P < 0.001). Furthermore, at the same concentration of NMDA, the cell survival rates were found to decrease with the increase of treatment time (F = 89.19, P < 0.001). In addition, there were interactions between concentration and time (F = 57.61, P < 0.001). Based on this result, 400 μM NMDA and 24 h were adopted as the moderate condition for the subsequent experiments. In addition, MK801 could effectively block NMDAinduced excitotoxicity (Fig. 2B) . These data indicated that NMDA could inhibit the survival rate of RGC-5 cells dose-and time-dependently; and this effect could be reversed by the addition of MK801.
DFO improved the survival of NMDA-treated RGC-5 cells
To investigate the effect of DFO on the NMDA-induced excitotoxicity in RGC-5 cells, DFO was added to the control RGC-5 cells or NMDA-treated RGC-5 cells at final concentrations of 5, 12.5, and 25 μM. Cells treated with NMDA (400 μM) + DFO were the experimental groups (NMDA+DFO). The cells received no treatment, NMDA only, and DFO only were considered as blank control group (Control), the negative control group (NMDA), and the positive control group (DFO), respectively. The results showed that higher doses of DFO (12.5 and 25 μM) could significantly reverse the inhibition induced by NMDA (Fig. 2B) . These data indicated that DFO could inhibit the NMDA-induced apoptosis in RGC-5 cells, and that this effect was positively correlated with the concentration of DFO. DFO improved the mitochondrial membrane potential in RGC-5 cells
Mitochondria are the most prominent locations in the cells for iron metabolism. In order to test whether the above process occurred during neuroprotective action of DFO, we studied mitochondrial transmembrane potential. RGC-5 cells were divided into four groups according to the treatments (i.e. control group: RGC-5 cells only; NMDA group: 400 μM NMDA; DFO group: 25 μM DFO only; and NMDA+DFO experimental group: 400 μM NMDA +25 μM DFO). The mitochondrial membrane potential in each group was assessed at 6 and 24 h. The results indicated that at both time points, the mitochondrial membrane potential was reduced by the treatment of NMDA compared with the control group, and the treatment of the DFO could significantly inhibit the effect inducted by NMDA at 24 h (Fig. 3), although not significantly at 6 h. These data indicated that NMDA could inhibit the mitochondrial membrane potential in RGC-5 cells, and DFO could reverse the inhibition effect of NMDA on mitochondrial membrane potential at long treatment time.
Effects of DFO on the expressions of the mitochondrial respiratory chain proteins
Iron ions play an important role in the mitochondrial respiratory chain. In order to investigate the mechanism behind this role, we selected two important mitochondrial respiratory chain proteins, succinate dehydrogenase complex subunit A (SDHA) and cytochrome c oxidase IV (COX IV).
We performed the immunofluorescent staining to analyze the intensity of fluorescence of SDHA in RGC-5 cells. The antibody against SDHA was used to further explore the mechanism by which DFO inhibited the NMDA-induced apoptosis in RGC-5 cells. The RGC-5 cells were divided into four groups (i.e. group 1: RGC-5; group 2: RGC-5 + 400 μM NMDA; group 3: RGC-5 + 25 μM DFO; and group 4: RGC-5 + 400 μM NMDA + 25 μM DFO). The immunofluorescence staining results showed that SDHA expression was inhibited by the addition of NMDA, while DFO reversed the effect of NMDA (Fig. 4A,B) . Subsequently, the expression levels of SDHA and COX IV were further assessed by western blot analysis. The intervention time was set at 24 h. As shown in Fig. 4C-E , NMDA reduced the expressions of SDHA and COX IV, while DFO increased their expression levels.
Discussion
The neurotoxic effects of glutamic acid were first reported in the middle of the 20th century. In 1957, Lucas et al. [12] subcutaneously injected glutamic acid in mice, and found that it induced structural injury in the inner retina. Olney et al. [13] first proposed the concept of excitotoxicity when they investigated the cytotoxicity of amino acids on the central nervous system of young rats [13] . In the present study, we found that the proliferation rate of RGC-5 cells cultured in vitro was distinctly lowered upon treatment with NMDA in a dose-dependent manner, and MK801 (NMDA receptor antagonist) could effectively block this pathway, suggesting that NMDA could induce injury or death in RGC-5 cells. NMDA directly acts on neurons and activates the NMDA receptors on the postsynaptic membrane, thus causing neuron excitotoxicity. This pathway simulates the excitotoxicity of glutamic acid-induced death of neurons during the pathogenesis of neurodegenerative diseases.
In recent years, NMDA-induced excitotoxicity has been well studied [14, 15] . Dexras1 is a GTPase protein which is homologous to the Ras subfamily. Activation of NMDA receptors in the brain can induce Dexras1 to regulate the uptake of iron ions. The activation of NMDA receptors stimulates the production of nNOS, which transmits high-valent nitrogen (NO) to Dexras1 after binding with CAPON, resulting in the nitrosation and activation of Dexras1. The nitrosated Dexras1 binds with PAP7, and then with the iron ion transporter DMT1, leading to increased uptake of iron ions. Chen et al. [16] discovered that Dexras1 regulated the NMDA-induced nervous excitotoxicity by the inflow of NO and iron ions, and that knocking out the Dexras1 gene could reduce NMDA-induced retinal ganglial cell death in mice. Thus, the NMDA-induced cell death is an iron ion-dependent process and this finding is also consistent with the results of multiple epidemiological studies in recent years. After an epidemiological investigation on 17,476 Korean cases, Lin et al. [17] demonstrated that elevated level of peripheral blood iron ion transporter ferretin was positively correlated with glaucomaassociated morbidity. In this study, the proliferation rate of RGC-5 cells was found to be lowered after NMDA intervention, which was likely associated with the increase in intracellular iron ions. When the level of free iron ions increases abnormally such that they cannot bind with proteins or ligands, they might catalyze and form ROS with metabolic toxicity through the H 2 O 2 -dependent Fenton reaction, attack biomacromolecules, and thus induce cell death [18] [19] [20] . In the case of neurodegenerative diseases, oxidative stress and neurotoxic factors produced due to oxidative stress could increase the mitochondrial fission [21, 22] .
DFO is an effective drug to treat iron overloads. It has been shown to possess antioxidant activity, and can chelate non-proteinbound iron, thus reducing products of oxidative stress, such as hydroxyl free radicals that are induced by elevated iron ions. Thus, DFO is considered to be a neuroprotectant [23, 24] and can be used in the treatment of neurodegenerative diseases such as Alzheimer's disease. It can remove iron from the plasma in vivo, effectively improving iron excretion and reducing iron content as well as pathological deposition in organs, thereby treating diseases such as acute iron poisoning and hemochromatosis [25, 26] . However, DFO is a very large molecule with low cell penetration. Although DFO is used for hemochromatosis, DFO does not directly remove iron from the vital organs such as the liver, rather it removes iron from the plasma. But in vitro, the results of this study showed that the survival rate of RGC-5 cells was increased after treatment with DFO, and this increase was positively correlated with the DFO concentration, even though the effect of DFO was marginal. Hence, we speculate that DFO may chelate iron from culture medium (containing 10% FBS) and DFO may play neuroprotective role by chelating iron from the extracellular environment. In addition, DFO might increase the baseline of cell vitality via some other pathways.
Mitochondria are the most prominent locations in the cells for iron metabolism. Reduction in the mitochondrial transmembrane potential, an irreversible event that occurs at the early stages of apoptosis [27] , can induce a series of biochemical changes both inside and outside the mitochondrial membrane. In order to test whether the above process occurred during neuroprotective action of DFO, we studied mitochondrial transmembrane potential. We found that the mitochondrial membrane potential reduced after NMDA intervention and then increased after the addition of 25 μM DFO. The results of this study suggest that such process is associated with mitochondria. In the event of an iron overload, iron ions enter the mitochondria via calcium transporters, bind with reactive oxygen species (ROS) intermediates through the Fenton reaction, and catalyze the formation of large amounts of ROS [28, 29] . The resulting excess ROS can induce a series of mitochondria-damaging reactions [30] [31] [32] . For instance, the release of caspase activator cytochrome C, which possesses the dual functions of regulating energy metabolism and apoptosis, can cause changes in the mitochondrial membrane permeability, activating proteins of the Bcl-2 family and caspases, resulting in a cascade reaction that eventually ends in apoptosis [33] . Apoptosis can be inhibited by suppressing the decrease in membrane potential. Thus, NMDA-induced nervous excitotoxicity results in increased iron inflow. Upon transport of iron ions in the mitochondria, large amounts of ROS are produced, which leads to a decrease in the mitochondrial membrane potential. DFO chelates iron ions, lowers ROS production, elevates membrane potential, and thus reduces apoptosis. This effect of DFO is consistent with the previously described results that DFO could increase the survival rate of RGC-5 cells in the present study.
Iron ions play an important role in the mitochondrial respiratory chain. In order to investigate the mechanism behind this role, we selected two important mitochondrial respiratory chain proteins, SDHA and COX IV. SDHA constitutes the SDH active center in the mitochondrial complex II. SDH transports the hydrogen ions from succinate to coenzyme Q in the citric acid cycle; the coenzyme Q is then reduced and becomes oxidatively stable after it receives hydrogen ion. If SDH loses its function or starts functioning abnormally, it will cause aggregation of succinate, deceased level of reduced coenzyme Q, and reduced oxidative stability, thus accelerating ROS production. Furthermore, SDH has also been shown to be involved in the regulation of mitochondrial complexes I and II to produce ROS [34, 35] . COX is the final link of the electron transport in the mitochondrial oxidation respiratory chain. Its expression level directly affects the enzyme activity and thus influences the mitochondrial function. Therefore, we selected SDHA and COX IV as the indices to reflect the mitochondrial function. Our results indicated that the expressions of SDHA and COX IV were distinctly reduced after NMDA intervention, suggesting that NMDA-induced nervous excitotoxicity damaged the mitochondrial function. It could block the citric acid cycle, cause a mitochondrial respiratory chain disorder, and increase ROS production. The addition of DFO was shown to up-regulate the expressions of SDHA and COX IV, thus improving mitochondrial function, reducing ROS production, and inhibiting apoptosis. Our results were similar to those obtained by Park et al. [36] who reported that DFO inhibited FAC-induced mitochondrial rupture and apoptosis. The expression levels of SDHA and COX IV were decreased after treatment with high concentrations of DFO, which was likely because DFO chelated excessive iron ions, which interfered with the siderophilous enzyme system and affected the metabolism of zinc and copper ions. SDHA is a flavoprotein with an iron-sulfur center, and the deficiency of iron ions may result in its reduced synthesis.
Dixon et al. [37] proposed a form of iron-dependent cell death (ferroptosis) while examining the mechanism of action of the small molecule, erastin, which killed tumor cells with a mutation in the oncogene RAS. Ferroptosis shares its cell transduction pathway with that of the excitotoxicity of glutamic acid, and both processes are iron-and ROS-dependent. Orrenius et al. [38] suspected that the oxidative neurotoxicity of glutamic acid might occur partly at the same time as an unknown type of cell death. After the discovery of the mechanism of ferroptosis, researchers began to speculate that the unknown type of death that Orrenius suspected might be ferroptosis. Iron serves as a prosthetic group for many important enzymes, and iron ion chelators with cell membrane permeability (such as CPX) or those without it (such as DFO) can prevent ferroptosis, regardless of whether it was induced physiologically, by erastin, or by RSL3 [39] . Iron chelators may inhibit ferroptosis by affecting the activities of important iron-containing enzymes. As discussed above, we speculate that DFO affects the activity of iron-containing enzymes to inhibit ferroptosis. This might partly explain DFO could improve mitochondrial function by raising the baseline of respiratory chain proteins, apart from the aforementioned oxidative stability of DFO.
In conclusion, DFO could exert significant neuroprotective effects on RGC-5 cells after NMDA-induced excitotoxicity via mitochondria, not only chelating iron from the extracellular environment to inhibit iron-dependent cell death, but also raising the baseline of respiratory chain proteins via some other pathways. But it does not simply interfere with the effect of NMDA. This study would help in the search for novel treatment targets and establish a theoretical foundation for the clinical treatment of neurodegenerative diseases. However, further experiments are still needed.
